Sesen Bio welcomes Dr. Peter Honig and Dr. Michael Jewett to its Board of Directors

– USA, MA –  Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the appointments of Dr. Peter Honig, MPH, and Dr. Michael Jewett, MD, FRCSC, FACS to its Bio Board of Directors.

Dr. Honig is the former SVP and Head of Global Regulatory Affairs and Group Head of Development China and Japan at Pfizer, while Dr. Jewett is a practicing Oncologist and global Key Opinion Leader.

“I am pleased to welcome Dr. Peter Honig and Dr. Michael Jewett to our Board of Directors,” said CEO, Dr. Thomas Cannell. “We have reached a transformational time for the Company as we approach the potential approval and launch of Vicineum in the US. We are very fortunate to add the deep global regulatory experience of Dr. Honig and the extensive clinical expertise of Dr. Jewett to further strengthen our Board. Their wealth of experience will be invaluable as we continue to make progress in bringing a potential best-in-class treatment to markets globally.”

About Dr. Peter Honig

Peter K Honig, MD, MPH is an experienced leader in the strategic and tactical aspects of medicine and vaccine development with expertise in clinical pharmacology, clinical programs, setting clinical trial design, compliance, medical product safety, and medical product regulation. Dr. Honig recently retired from Pfizer as SVP and Head of Global Regulatory Affairs and Group Head of Development China and Japan. Dr. Honig led Pfizer’s commitment to patient safety by working across the organization to ensure regulatory effectiveness, quality control, and compliance throughout all stages of product development and post-approval. Before joining Pfizer, he held senior leadership positions at AstraZeneca and Merck Research Laboratories and with the FDA, including a role as the first Director of the Office of Drug Safety in the FDA’s Center for Drug Evaluation and Research.

In addition to his industry and FDA experience, Dr. Honig has been the PhRMA representative to the International Conference on Harmonisation Steering Committee from 2002 to 2021, is a past President of the American Society for Clinical Pharmacology, and Therapeutics and is currently an associate editor of their flagship journal. Dr. Honig received medical and public health degrees from Columbia University in New York.

“I am honored to join the Sesen Bio Board of Directors,” said Dr. Honig. “Sesen Bio has made tremendous progress in key markets with the upcoming potential product approvals in the US in August and in Europe in 2022 with a promising pipeline to fuel future growth. I look forward to working with the Board and management team in contributing to Sesen Bio’s future success.”

About Dr. Michael Jewett

Michael A.S. Jewett, MD, FRCSC, FACS is a prominent Oncologist who is internationally recognized for his life-saving innovations in surgical oncology, his advocacy of patient-centered clinical care, and his contributions to research in the field of bladder cancer. Dr. Jewett is currently a professor in the Departments of Surgical Oncology and Surgery at the Princess Margaret Cancer Centre, University Health Network, and the University of Toronto. A graduate of Queen’s University, Faculty of Medicine, Kingston, Ontario, Canada, where BCG for bladder cancer was first prescribed, Dr. Jewett completed his Urology training at the University of Toronto, Canada, and Memorial Sloane-Kettering Cancer Center in New York. Dr. Jewett has played a leading role in national and international consensus statements, including as a committee chair for the International Consultation on Bladder Tumors in the 2004 Consensus. He has appeared before the FDA as an expert including the presentation that led to the historic approval of BCG for NMIBC. Dr. Jewett has published more than 400 peer-reviewed papers, mostly in Uro-oncology and in technology assessment and medical informatics. Dr. Jewett was a member of the inaugural Medical Advisory Board of the Bladder Cancer Advocacy Network. He is an Honorary Member of the American Urological Association and the European Association of Urology and has been a visiting professor in more than 40 institutions and associations. In December 2020, Dr. Jewett was appointed to the Order of Canada based on his achievements listed above, among others.

“It is a pleasure to join the Sesen Bio Board of Directors at such an exciting time in the Company’s evolution,” said Dr. Jewett. “I have been watching the progress of Vicineum carefully for more than 10 years and I am delighted with the progress. I believe Vicineum has the potential to transform the way Urologists treat patients with BCG-unresponsive NMIBC with promising expansion potential into earlier treatment intervention and possible combination regimens with checkpoint inhibitors. I look forward to working with the talented leadership team as they continue to execute on their mission of saving and improving the lives of patients with cancer.”

About Sesen Bio

Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company’s lead program, Vicineum, also known as oportuzumab monatox, is currently in the follow-up stage of a Phase 3 registration trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. In February 2021, the FDA accepted for filing the Company’s BLA for Vicineum for the treatment of BCG-unresponsive NMIBC and granted the application Priority Review with a target PDUFA date of August 18, 2021. Sesen Bio retains worldwide rights to Vicineum except for Greater China and the Middle East and North Africa, for which the Company has partnered with Qilu Pharmaceutical and Hikma Pharmaceuticals, respectively, for commercialization. Vicineum is a locally administered targeted fusion protein composed of an anti-EpCAM antibody fragment tethered to a truncated form of Pseudomonas Exotoxin A, which is being developed for the treatment of BCG-unresponsive NMIBC.

For more information: https://sesenbio.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.